PAVmed (NASDAQ: PAVM) is one of 112 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare PAVmed to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Institutional & Insider Ownership
6.7% of PAVmed shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 29.2% of PAVmed shares are owned by company insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of current recommendations and price targets for PAVmed and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PAVmed presently has a consensus price target of $5.00, suggesting a potential upside of 270.37%. As a group, “Surgical & medical instruments” companies have a potential upside of 2.58%. Given PAVmed’s stronger consensus rating and higher possible upside, equities analysts clearly believe PAVmed is more favorable than its competitors.
Volatility & Risk
PAVmed has a beta of -0.62, indicating that its stock price is 162% less volatile than the S&P 500. Comparatively, PAVmed’s competitors have a beta of 0.82, indicating that their average stock price is 18% less volatile than the S&P 500.
This table compares PAVmed and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares PAVmed and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|PAVmed Competitors||$1.46 billion||$105.27 million||-194.65|
PAVmed’s competitors have higher revenue and earnings than PAVmed. PAVmed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
PAVmed beats its competitors on 7 of the 13 factors compared.
PAVmed Company Profile
PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.